Clinical trials for Endometrial cancer

128 currently recruiting clinical trials
Phase 1 / Phase 2 Endometrial cancer #NCT04585750 #2023-504251-27-00
Phase 2 cohorte de patients atteints d'un cancer de l'endomètre
Locally Advanced Metastatic TP53 1 2 3 or more
KRAS G12C KRAS non G12C Systemic Treatment-Naive
9 recruiting sites
PMV Pharmaceuticals, Inc
Phase 1 / Phase 2 Breast cancer Lung cancer Prostate cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer Thymus cancer Penile cancer and germ cell tumors Cervical / Vulvar / Vaginal cancer #NCT05768139 #2023-000442-41
Cohortes autres tumeurs solides
Oral cavity Nasopharynx Oropharynx Hypopharynx Larynx Nasal cavities and sinuses Squamous cell carcinoma HR Positive Locally Advanced Metastatic PIK3CA 1 2 3 or more
6 recruiting sites
Eli Lilly et compagnie
Phase 1 / Phase 2 Breast cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer Sarcoma and GIST Thymus cancer Penile cancer and germ cell tumors #NCT05118789
Locally Advanced Metastatic ROS-1 1
4 recruiting sites
Nuvalent Inc.
Phase 1 / Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer #NCT04657068 #2024-511534-12-00
Parties A1, A2, A3 (escalade de dose)
Locally Advanced Metastatic Metastatic Castration-resistant ATM 1 2 3 or more
Systemic Treatment-Naive
5 recruiting sites
Artios Pharma Ltd
Phase 1 / Phase 2 Endometrial cancer #NCT04657068 #2024-511534-12-00
Dose d'expansion Partie B3
Locally Advanced Metastatic ATM 1 2 3 or more Chemotherapy
Systemic Treatment-Naive
5 recruiting sites
Artios Pharma Ltd
Phase 1 / Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer #NCT04657068 #2024-511534-12-00
Dose d'expansion Partie B4
Locally Advanced Metastatic Metastatic Castration-resistant ATM 1 2 3 or more
Systemic Treatment-Naive
5 recruiting sites
Artios Pharma Ltd
Phase 1 / Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer #NCT04657068 #2024-511534-12-00
Dose d'expansion Partie B1
Locally Advanced Metastatic Metastatic Castration-resistant ATM 1 2 3 or more
Systemic Treatment-Naive
5 recruiting sites
Artios Pharma Ltd
Phase 1 / Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer #NCT06833008 #2024-519184-18-00
Metastatic Other KRAS BRAF KRAS G12C KRAS non G12C NRAS HRAS KRAS G12D
Systemic Treatment-Naive
2 recruiting sites
Ipsen
Phase 1 / Phase 2 Breast cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer #NCT05443126 #2022-501636-42-00
Cohorte Autres tumeurs tumeurs solides présentant une altération du gène RET naïves de traitement par inhibiteurs sélectifs de RET de première génération
Locally Advanced Metastatic RET 1 2 3 or more
Systemic Treatment-Naive Targeted therapy
4 recruiting sites
Ellipses Pharma
Phase 1 / Phase 2 Breast cancer Prostate cancer Colon cancer Rectal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer #NCT05443126 #2022-501636-42-00
Cohorte Autres tumeurs tumeurs solides présentant une altération du gène RET pré-traitrées par inhibiteurs sélectifs de RET de première génération
Locally Advanced Metastatic Metastatic Castration-resistant RET 1 2 3 or more Targeted therapy
Systemic Treatment-Naive
4 recruiting sites
Ellipses Pharma